Related Experiment Video

Updated: Jun 30, 2026

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

High risk neuroblastoma: a persistent therapeutic challenge

Alberto Garaventa1, Giorgio Perilongo

  • 1Division of Haematology-Oncology, Hospital Giannina Gaslini, Genova-Quarto, Italy.

Pediatric Blood & Cancer
|September 27, 2008
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Experiment Videos

Last Updated: Jun 30, 2026

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Pediatric blood & cancer·2026

Missense but mis-spliced: germline TP53 variant c.671A > C (p.E224A) and the path from uncertainty to pathogenicity.

Scientific reports·2026

Retrospective Analysis of Incidence and Etiology of Severe Infections in Children Receiving Therapy for High-Risk Neuroblastoma: A Large Single-Center Experience.

Pediatric blood & cancer·2026

Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.

British journal of haematology·2026

A Computational Approach to Evaluating Empirical Antibiotic Coverage for Gram-Negative Bloodstream Infections in Pediatric Febrile Neutropenia.

Antibiotics (Basel, Switzerland)·2026

Aging and rare diseases: from epidemiology to a call to action.

European geriatric medicine·2026

Pegaspargase Rechallenge Following Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 16-001.

Pediatric blood & cancer·2026

Baseline Risk of Treatment Abandonment and Survival of Children With Common and Curable Cancers in the Zero Abandonment Cash Transfer Programme-A Multi-Centre Prospective CANCaRe Africa Study.

Pediatric blood & cancer·2026

Time to Diagnosis Among Children and Adolescents With Cancer in Québec, Canada: A Population-Based Study.

Pediatric blood & cancer·2026

Low Dasatinib Penetration of the Blood-Brain Barrier in Children With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Evidence From LC-MS/MS Analysis.

Pediatric blood & cancer·2026

Radiological Late Dental Adverse Effects Following Treatment for Paediatric Head and Neck Rhabdomyosarcoma: Results of a Transatlantic Multicentre Cohort Study.

Pediatric blood & cancer·2026

Outcomes of Children With Orbital Rhabdomyosarcoma, 1991-2016: A Report From the International Soft Tissue Sarcoma Consortium (INSTRuCT).

Pediatric blood & cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us